RU2015144149A - Протеомные маркеры илф - Google Patents
Протеомные маркеры илф Download PDFInfo
- Publication number
- RU2015144149A RU2015144149A RU2015144149A RU2015144149A RU2015144149A RU 2015144149 A RU2015144149 A RU 2015144149A RU 2015144149 A RU2015144149 A RU 2015144149A RU 2015144149 A RU2015144149 A RU 2015144149A RU 2015144149 A RU2015144149 A RU 2015144149A
- Authority
- RU
- Russia
- Prior art keywords
- fibrotic disease
- pulmonary
- subject
- pulmonary fibrotic
- expression level
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361801476P | 2013-03-15 | 2013-03-15 | |
| US201361801290P | 2013-03-15 | 2013-03-15 | |
| US61/801,290 | 2013-03-15 | ||
| US61/801,476 | 2013-03-15 | ||
| US201361874947P | 2013-09-06 | 2013-09-06 | |
| US61/874,947 | 2013-09-06 | ||
| PCT/US2014/029392 WO2014144821A1 (en) | 2013-03-15 | 2014-03-14 | Proteomic ipf markers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2015144149A true RU2015144149A (ru) | 2017-04-21 |
Family
ID=51537804
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015144149A RU2015144149A (ru) | 2013-03-15 | 2014-03-14 | Протеомные маркеры илф |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9726677B2 (enExample) |
| EP (1) | EP2972392A4 (enExample) |
| JP (1) | JP2016519763A (enExample) |
| KR (1) | KR20150130408A (enExample) |
| CN (1) | CN105122068A (enExample) |
| BR (1) | BR112015023699A2 (enExample) |
| CA (1) | CA2901384A1 (enExample) |
| HK (1) | HK1219533A1 (enExample) |
| MX (1) | MX2015012778A (enExample) |
| RU (1) | RU2015144149A (enExample) |
| WO (1) | WO2014144821A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10236078B2 (en) | 2008-11-17 | 2019-03-19 | Veracyte, Inc. | Methods for processing or analyzing a sample of thyroid tissue |
| EP3360978A3 (en) | 2009-05-07 | 2018-09-26 | Veracyte, Inc. | Methods for diagnosis of thyroid conditions |
| US11976329B2 (en) | 2013-03-15 | 2024-05-07 | Veracyte, Inc. | Methods and systems for detecting usual interstitial pneumonia |
| US9726677B2 (en) | 2013-03-15 | 2017-08-08 | Intermune, Inc. | Proteomic IPF markers |
| US12297505B2 (en) | 2014-07-14 | 2025-05-13 | Veracyte, Inc. | Algorithms for disease diagnostics |
| CN114606309A (zh) | 2014-11-05 | 2022-06-10 | 威拉赛特公司 | 使用机器学习和高维转录数据的诊断系统和方法 |
| US10975167B2 (en) | 2017-04-14 | 2021-04-13 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Method to reduce pulmonary arterial hypertension by administering inhibitors of nicotinamide phosphoribotransferase |
| EP3610018B1 (en) * | 2017-04-14 | 2023-06-07 | Arizona Board of Regents on Behalf of the University of Arizona | Compositions and methods for treating pulmonary fibrosis |
| CN107677835B (zh) * | 2017-09-26 | 2019-08-09 | 上海市肺科医院 | 一种ae-ipf的蛋白标记物及其应用 |
| CN113260863A (zh) * | 2018-08-17 | 2021-08-13 | 豪夫迈·罗氏有限公司 | 用于心房纤颤的评价中的循环bmp10 (骨形态发生蛋白10) |
| CN112969921B (zh) * | 2018-10-29 | 2024-06-07 | 国立大学法人东京医科齿科大学 | 取得间质性肺炎患者的呼吸功能的降低风险相关信息的方法及其利用 |
| JP7300642B2 (ja) * | 2019-06-14 | 2023-06-30 | 国立大学法人浜松医科大学 | 特発性肺線維症の予後予測方法 |
| CN110333358A (zh) * | 2019-06-24 | 2019-10-15 | 浙江大学 | 一种急性肺损伤小鼠肺脏全免疫细胞特征图谱的建立方法 |
| WO2021024856A1 (ja) * | 2019-08-02 | 2021-02-11 | 国立医薬品食品衛生研究所長が代表する日本国 | 間質性肺炎のタンパク質診断バイオマーカー |
| US20230129866A1 (en) * | 2020-03-13 | 2023-04-27 | Puretech Lyt 100, Inc. | Methods of treating respiratory disease with deupirfenidone |
| CN115702351B (zh) * | 2020-04-17 | 2026-03-31 | 国立医药品食品卫生研究所长 | 重症药疹的蛋白质诊断生物标记物 |
| CN113607955A (zh) * | 2020-09-16 | 2021-11-05 | 广州中医药大学顺德医院(佛山市顺德区中医院) | 新型冠状病毒肺炎分期与疗效评估细胞因子标志物及其应用 |
| CN113533750A (zh) * | 2020-10-22 | 2021-10-22 | 广州中医药大学顺德医院(佛山市顺德区中医院) | 一种区分新型冠状病毒肺炎患者与健康者的系统 |
| WO2023038416A1 (ko) * | 2021-09-07 | 2023-03-16 | 주식회사 에프엔씨티바이오텍 | 폐 섬유증의 바이오마커 및 치료 표적으로서 csf3r |
| US20230147720A1 (en) * | 2021-11-05 | 2023-05-11 | Spiritus Therapeutics, Inc. | Purified Enriched Population Exosomes Derived From Individuals With A Chronic Progressive Lung Disease For Noninvasive Detection, Staging, And Medical Monitoring Of Disease Progression |
| CN114563562A (zh) * | 2022-03-01 | 2022-05-31 | 复旦大学附属中山医院 | Prdx6联合铁离子检测在ards进程监测中的应用 |
| KR102907646B1 (ko) * | 2022-08-19 | 2026-01-05 | 울산대학교 산학협력단 | 특발성 폐섬유증 환자의 진단 및 경과예측용 호기 바이오마커 |
| CN119947728A (zh) * | 2022-09-28 | 2025-05-06 | 勃林格殷格翰国际有限公司 | 生物标志物在用pde4b抑制剂治疗纤维化病症中的用途 |
| CN117025745B (zh) * | 2022-11-18 | 2024-02-23 | 中国医学科学院北京协和医院 | 分子标志物在诊断干燥综合征中的应用 |
| WO2026069490A1 (ja) * | 2024-09-25 | 2026-04-02 | 国立大学法人大阪大学 | 進行性肺線維症診断用バイオマーカー、該バイオマーカーを用いた進行性肺線維症の検査方法及びそれらの利用 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| US5235033A (en) | 1985-03-15 | 1993-08-10 | Anti-Gene Development Group | Alpha-morpholino ribonucleoside derivatives and polymers thereof |
| US5637459A (en) | 1990-06-11 | 1997-06-10 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: chimeric selex |
| US5496938A (en) | 1990-06-11 | 1996-03-05 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligands to HIV-RT and HIV-1 rev |
| US5582981A (en) | 1991-08-14 | 1996-12-10 | Gilead Sciences, Inc. | Method for identifying an oligonucleotide aptamer specific for a target |
| US6019988A (en) * | 1996-11-18 | 2000-02-01 | Bristol-Myers Squibb Company | Methods and compositions for enhancing skin permeation of drugs using permeation enhancers, when drugs and/or permeation enhancers are unstable in combination during long-term storage |
| JP4406206B2 (ja) * | 2001-04-24 | 2010-01-27 | バイエル コーポレーション | ヒトｔｉｍｐ−１抗体 |
| AUPR638101A0 (en) * | 2001-07-13 | 2001-08-09 | Bioa Pty Limited | Composition and method for treatment of disease |
| JP2003238592A (ja) * | 2001-12-13 | 2003-08-27 | Japan Tobacco Inc | 組織及び血管の再生のための医薬及びその方法 |
| US20040131614A1 (en) | 2002-07-19 | 2004-07-08 | Abbott Biotechnology Ltd. | Treatment of pulmonary disorders using TNFalpha inhibitor |
| US7888485B2 (en) * | 2003-03-26 | 2011-02-15 | Georgetown University | Anti-pleiotrophin antibodies and methods of use thereof |
| US20060211752A1 (en) * | 2004-03-16 | 2006-09-21 | Kohn Leonard D | Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression |
| ES2303925T3 (es) * | 2004-08-12 | 2008-09-01 | F. Hoffmann-La Roche Ag | Metodo para diagnosticar la fibrosis hepatica. |
| WO2006088925A2 (en) * | 2005-02-14 | 2006-08-24 | Wyeth | Use of il17-f in diagnosis and therapy of airway inflammation |
| EP1757940A1 (en) * | 2005-08-26 | 2007-02-28 | Cézanne S.A.S. | In vitro method for diagnosing and monitoring renal cell carcinoma (RCC) using MMP-7 as humoral biomarker for RCC |
| US20110129845A1 (en) * | 2007-01-29 | 2011-06-02 | Crc For Asthma And Airways Ltd. | Method of diagnosis |
| EP2190478B1 (en) * | 2007-08-24 | 2016-03-23 | Oncotherapy Science, Inc. | Dkk1 oncogene as therapeutic target for cancer and a diagnosing marker |
| WO2010028274A1 (en) | 2008-09-05 | 2010-03-11 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Marker panels for idiopathic pulmonary fibrosis diagnosis and evaluation |
| US8568996B2 (en) * | 2008-10-21 | 2013-10-29 | University of Pittsburgh—of the Commonwealth System of Higher Education | MMP activation peptide detection in biological samples |
| WO2010083392A2 (en) | 2009-01-16 | 2010-07-22 | The Ohio State University Research Foundation | Ets-2 biomarkers for fibrotic diseases and uses thereof |
| US20100227335A1 (en) * | 2009-03-05 | 2010-09-09 | Becton, Dickinson And Company | Matrix metalloproteinase-7 (mmp-7) monoclonal antibodies and methods for their use in the detection of ovarian cancer |
| AU2010229705A1 (en) * | 2009-03-27 | 2011-10-20 | Zymogenetics, Inc. | Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination |
| RU2012110580A (ru) * | 2009-08-21 | 2013-09-27 | Джилид Байолоджикс, Инк. | Способы скрининга in vivo |
| EP2496944A2 (en) | 2009-11-05 | 2012-09-12 | Novartis AG | Biomarkers predictive of progression of fibrosis |
| WO2011091270A2 (en) | 2010-01-21 | 2011-07-28 | The Regents Of The University Of Michigan | Biomarkers for lung disease monitoring |
| AU2012312515A1 (en) * | 2011-09-19 | 2014-03-13 | Genentech, Inc. | Combination treatments comprising c-met antagonists and B-raf antagonists |
| US9726677B2 (en) | 2013-03-15 | 2017-08-08 | Intermune, Inc. | Proteomic IPF markers |
-
2014
- 2014-03-14 US US14/213,970 patent/US9726677B2/en active Active - Reinstated
- 2014-03-14 CA CA2901384A patent/CA2901384A1/en not_active Abandoned
- 2014-03-14 WO PCT/US2014/029392 patent/WO2014144821A1/en not_active Ceased
- 2014-03-14 HK HK16107519.9A patent/HK1219533A1/zh unknown
- 2014-03-14 BR BR112015023699A patent/BR112015023699A2/pt not_active IP Right Cessation
- 2014-03-14 RU RU2015144149A patent/RU2015144149A/ru unknown
- 2014-03-14 KR KR1020157027988A patent/KR20150130408A/ko not_active Withdrawn
- 2014-03-14 EP EP14762377.1A patent/EP2972392A4/en not_active Withdrawn
- 2014-03-14 MX MX2015012778A patent/MX2015012778A/es unknown
- 2014-03-14 CN CN201480021359.5A patent/CN105122068A/zh active Pending
- 2014-03-14 JP JP2016503081A patent/JP2016519763A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP2972392A4 (en) | 2017-03-22 |
| US20140286929A1 (en) | 2014-09-25 |
| BR112015023699A2 (pt) | 2017-07-18 |
| EP2972392A1 (en) | 2016-01-20 |
| JP2016519763A (ja) | 2016-07-07 |
| CA2901384A1 (en) | 2014-09-18 |
| KR20150130408A (ko) | 2015-11-23 |
| HK1219533A1 (zh) | 2017-04-07 |
| WO2014144821A1 (en) | 2014-09-18 |
| US9726677B2 (en) | 2017-08-08 |
| CN105122068A (zh) | 2015-12-02 |
| MX2015012778A (es) | 2016-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016519763A5 (enExample) | ||
| Staudacher et al. | Use of endotypes, phenotypes, and inflammatory markers to guide treatment decisions in chronic rhinosinusitis | |
| Arron et al. | Noninvasive biomarkers that predict treatment benefit from biologic therapies in asthma | |
| Arms et al. | Expression and function of CCL2/CCR2 in rat micturition reflexes and somatic sensitivity with urinary bladder inflammation | |
| HK1258292A1 (zh) | 使用il23途径生物标志物预测il23拮抗剂的临床应答 | |
| JP6755242B2 (ja) | 新規分子バイオマーカーを使用して慢性閉塞性肺疾患（ｃｏｐｄ）を診断する方法 | |
| JP6755241B2 (ja) | 新規分子バイオマーカーを使用して慢性閉塞性肺疾患（ｃｏｐｄ）を診断する方法 | |
| JP6755240B2 (ja) | 新規分子バイオマーカーを使用して慢性閉塞性肺疾患（ｃｏｐｄ）を診断する方法 | |
| RU2015108959A (ru) | Способы прогнозирования риска развития гипертензии | |
| JP2010516678A5 (enExample) | ||
| EP2503338A3 (en) | CD73 as a biomarker for monitoring development of diseases and assessing the efficacy of therapies | |
| BR112015023699A2 (pt) | método de determinação de um nível de expressão de uma proteína marcadora de doença pulmonar fibrótica, método de determinação se um indivíduo tem ou está em risco de desenvolvimento de uma doença pulmonar fibrótica, método de determinação se um paciente de doença pulmonar fibrótica está em risco de progressão da doença pulmonar fibrótica, método de determinação de uma atividade de doença pulmonar fibrótica em um paciente, e método de tratamento de uma doença pulmonar fibrótica em um indivíduo em necessidade do mesmo | |
| US20160178584A1 (en) | Methods for diagnosing and assessing kidney disease | |
| JPWO2018008764A1 (ja) | 軽度認知障害又はアルツハイマー型認知症の評価方法 | |
| JP2015500988A (ja) | 肺障害のバイオマーカーとしてのｌｔｂｐ２ | |
| RU2014145259A (ru) | Прогнозирование нежелательных явлений у пациентов с предполагаемым диагнозом хронической сердечной недостаточности | |
| JP2008536480A5 (enExample) | ||
| Stefaniak et al. | Macrophage migration inhibitory factor as a potential predictor for requirement of renal replacement therapy after orthotopic liver transplantation | |
| JP2024023615A (ja) | 感染性疾患の症状を有する患者において入院を必要とする病状のリスクを予測するためのｐｒｏ－ａｄｍ | |
| CN107345970A (zh) | 一种可用于首发精神分裂症诊断的外周血生物标志物 | |
| US8309299B2 (en) | Combination therapy and method for assessing resistance to treatment | |
| JP2023041741A (ja) | 重篤患者用の療法モニタリングマーカーとしてのｐｒｏ－ａｄｍ | |
| RU2016147122A (ru) | Применение серелаксина для снижения gdf-15 | |
| JP2019502902A5 (enExample) | ||
| CN102300875B (zh) | 肾病相关的生物标记 |